Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 19:01:50 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Xspray Pharma Q3 2023 - Approaching Commercialization

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Xspray Pharma Q3 2023 - Approaching Commercialization

2023-11-09 08:44:00

Redeye makes minor changes to its fair value range following Xspray Pharma’s Q3 report, which contained no major surprises. We continue to observe a disconnect between operational newsflow and the share price as Xspray proceeds toward FDA approval and the anticipated Q3 2024 launch of Dasynoc.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/